GLORIA BARNETT-DUNCAN: Open Payments
NPI 1346627064 · HYANNIS, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,344 in 48 payments from 14 companies in 2025. Trend: 2023 $587 · 2024 $595 · 2025 $1,344
Food & beverage: $1,344
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $415 |
| Axsome Therapeutics, Inc. | 3 | $179 |
| Vanda Pharmaceuticals Inc. | 6 | $153 |
| E.R. Squibb & Sons, L.L.C. | 4 | $106 |
| ABBVIE INC. | 4 | $99 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $97 |
| Teva Pharmaceuticals USA, Inc. | 4 | $83 |
| Janssen Pharmaceuticals, Inc | 2 | $57 |
| Luye Pharma (USA) Ltd. | 2 | $37 |
| Neurocrine BioSciences, Inc. | 1 | $28 |
Products named: REXULTI, Auvelity, FANAPT, COBENFY, VRAYLAR, CAPLYTA, AUSTEDO XR, INVEGA SUSTENNA.
Industry payments across MA — which companies pay providers there.
